External partners and affiliates

REMAP-ILD: Randomised, embedded, multifactorial, adaptive platform trial for interstitial lung disease

An inclusive global collaborative project which will develop the first international platform trial in Interstitial Lung Disease (ILD), accelerating identification of effective and novel therapies in fibrotic ILD (FILD). Find out more on our Research pages. 

UK-ILD

New national study will investigate the long-term effects of lung inflammation and scarring from COVID-19. Find out more on the UKRI webpages.

HEAL-COVID

This national clinical trial aims to identify treatments that may be beneficial for people discharged from hospital after recovering from COVID-19. Find out more on their webpages.

PHOSP-COVID

A consortium of leading researchers and clinicians from across the UK working together to understand and improve long-term health outcomes for patients who have been in hospital with confirmed or suspected COVID-19. Find out more on their webpages.

Genomics England Clinical Interpretation Partnership

Researchers and clinicians, from both academia and the NHS, are working together to continually analyse data from the 100,000 Genomes Project. They have joined the Genomics England Clinical Interpretation Partnership (GeCIP), forming either disease-facing or functional groups or ‘domains’. Find out more on their webpages.

UKRI DEMISTIFI

Through understanding the clusters of Fibrotic Multi-Morbidity and mapping them to the mechanisms of available therapies, the DEMISTIFI consortium will aim to prevent the development of long term Fibrotic Multi-Morbidity. Find out more on UKRI webpages.